FDA Approves Apretude, the First, Only Long-acting Injectable Option for HIV Prevention
December 22nd 2021The agency’s approval follows trial results demonstrating the superior efficacy of the cabotegravir long-acting injectable to a daily oral PrEP option in reducing the risk of infection.
Read More
Expert: Pharmacists, USP Worked Together ‘A Hundred Times Faster Than Ever Before’ in 2021
December 22nd 2021Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.
Watch
TXNIP inhibitors: A New Class of Agents for Diabetes Treatment
TXNIP inhibition could prevent beta cell loss and protect beta cell function to potentially contribute to diabetes management and its complications.
Read More
Assessing Trial Results for All Endpoints for Dara-KRd in Treatment of Multiple Myeloma
December 22nd 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the results for all of the trial endpoints assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma.
Watch
Safety, Efficacy of BOVen Therapy in Patients With Previously Untreated CLL
December 22nd 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.
Watch
Link Is Seen to Commonly Screened Protein During Pregnancy
December 22nd 2021The data highlight a new role for pregnancy-associated plasma protein A, known as PAPP-A, in gestational diabetes, with translational potential as both a diagnostic tool and therapeutic target, according to the investigators.
Read More
Assessing the Primary Endpoint Trial Results for Dara-KRd in Treatment of Multiple Myeloma
December 21st 2021Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the primary endpoint in the trial assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone in the treatment of patients with newly diagnosed multiple myeloma.
Watch
Assessing Adverse Events From BOVen Therapy in Patients With Previously Untreated CLL
December 21st 2021Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses the adverse events experienced by patients with previously untreated chronic lymphocytic leukemia when treated with zanubrutinib, obinutuzumab, and venetoclax.
Watch